There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD40 Ligand

CD40 Ligand

CD40 Ligand Molecule Information

Name:CD40 ligand
Target Synonym:CD40 ligand;T-cell antigen Gp39;CD40-L;TNFSF5;CD40LG;CD40L ;TRAP;CD40 ligand, soluble form;CD40 ligand, membrane form;Tumor necrosis factor ligand superfamily member 5;TNF-related activation protein;CD_antigen=CD154
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:13
Lastest Research Phase:Phase ?

CD40 Ligand Protein Product ListCompare or Buy

CD40 Ligand Molecule Synonym Name


CD40 Ligand Molecule Background

CD40 ligand is also known as CD40L, CD154, TNFSF5 and T-cell antigen Gp39, is a single-pass type I I membrane protein which belongs to the TNF superfamily of molecules. CD40 ligand is expressed predominantly on activated CD4+ T lymphocytes, and also found in other types of cells, including platelets, mast cells, macrophages, basophils, NK cells, B lymphocytes, as well as non-haematopoietic cells (smooth muscle cells, endothelial cells, and epithelial cells). Although all monomeric, dimeric and trimeric forms of soluble CD40 ligand can bind to CD40, the trimeric form of soluble CD40 ligand has the most potent biological activity through oligomerization of cell surface CD40, a common feature of TNF receptor family members. CD40 ligand binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In general, CD40 ligand plays the role of a costimulatory molecule and induces activation in APC in association with T cell receptor stimulation by MHC molecules on the APC. In total CD40 ligand has three binding partners: CD40, ¦Á5¦Â1 integrin and ¦ÁIIb¦Â3. CD40 ligand regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper IgM syndrome.

CD40 Ligand References

  • Sch

    CD40 Ligand Related Molecule

    CD40 Ligand Clinical Drug Information

    Name Research Code Research Phase Company Indications Clinical Trials
    CD154 gene therapy (Tragen) Ad-ISF154; ISF-154 Phase Ⅱ University of California San Diego, Tragen Pharmaceuticals Chronic lymphocytic leukemia (CLL) Details
    MEDI-4920 MEDI-4920; VIB-4920,MEDI4920; VIB4920 Phase Ⅱ MedImmune, Viela Bio Rejection of renal transplantation Details
    Toralizumab IDEC-131; E-6040 Phase Ⅱ Seikagaku, Biogen, Eisai Autoimmune diseases, Psoriasis, Systemic lupus erythematosus, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Idiopathic thrombocytopenic purpura (ITP), Crohn's disease Details
    Anti-CD40L antibody (Bristol-Myers Squibb) Phase Ⅱ Bristol-Myers Squibb Immunodeficiency disorders Details
    INX-021 INX-021; SAR-441344 Phase Ⅰ ImmuNext, Sanofi Multiple sclerosis (MS) Details
    ABBV-428 ABBV-428; ABBV428 Phase Ⅰ Abbvie Solid tumours Details
    Delolimogene mupadenorepvec LOAd-703 Phase Ⅱ Uppsala University, Lokon Pharma Colorectal cancer, Ovarian cancer, Pancreatic cancer, Biliary cancer Details
    Ruplizumab BG-9588 Phase Ⅱ Biogen Hemophilia A, Autoimmune diseases, Systemic lupus erythematosus, Immune thrombocytopenic purpura, Multiple sclerosis (MS), Rejection of renal transplantation Details
    BIIB-063 BIIB-063 Phase Ⅰ Biogen Sjoegren's syndrome Details
    Dapirolizumab pegol CDP-7657; Anti-CD40L-Fab; Anti-CD40L-Fab-PEG; CD40L - Fab,CDP7657 Phase Ⅱ Biogen, UCB Systemic lupus erythematosus Details
    rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA,rVV 740CTA Phase Ⅰ University Hospital Basel Breast cancer Details
    Letolizumab BMS-986004; BMS2h-572-633-CT-L2 ,BMS986004 Phase Ⅱ Bristol-Myers Squibb Immune thrombocytopenic purpura Details
    AdCD40L Phase Ⅱ Uppsala University Bladder cancer, Melanoma Details

This web search service is supported by Google Inc.